PL
CRMD icon

Parkwood LLC’s CorMedix CRMD Stock Holding History

Parkwood LLC’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-29,576
Closed -$294K – 437
2015
Q3 		$294K Buy
29,576
+14,840
+101% +$229K 0.05% 361
2015
Q2 		$286K Buy
14,736
+2,586
+21% +$88.7K 0.04% 431
2015
Q1 		$598K Buy
+12,150
New +$288K 0.07% 167

Other funds holding CRMD

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Parkwood LLC's CRMD Position: Q4 2015 in Review

Parkwood LLC sold out of CorMedix (CRMD) in Q4 2015, closing a stake of 29,576 shares — an estimated $294K sold.

Parkwood LLC first reported a position in CRMD in Q1 2015 and held it in 3 quarters. The position peaked at $598K in Q1 2015. 52 funds tracked by Wall St. Rank hold CRMD as of Q4 2015.

  • Parkwood LLC reported no remaining CorMedix position as of Q4 2015 after selling out during the quarter.
  • Parkwood LLC sold 29,576 CorMedix shares in Q4 2015, an estimated $294K.
  • Parkwood LLC first reported a position in CorMedix in Q1 2015 and held it in 3 quarters.
  • Parkwood LLC's CorMedix position peaked at $598K in Q1 2015.
  • 52 funds tracked by Wall St. Rank held CorMedix as of Q4 2015.

Based on Parkwood LLC's 13F filing for Q4 2015, filed 4 Feb 2016.